Eli Lilly’s New Weight Loss Drug Shows Groundbreaking Results in Trials
Eli Lilly is set to commence phase 3 trials for its novel weight loss drug, eloralintide, following encouraging results from early studies. This amylin analog, which slows digestion and curbs appetite, has shown significant weight loss and health improvements in patients.
Eloralintide, an amylin analog, has demonstrated remarkable potential in early trials. Patients lost between 9.5% to 20.1% of their body weight, with less lean muscle mass loss compared to GLP-1 drugs. Additionally, patients experienced improvements in blood pressure, blood fat levels, and inflammation markers. Eli Lilly plans to seek approval for eloralintide after successful phase 3 trials.
Novo Nordisk's amylin analog, cagrilintide, has also shown promise. In early studies, it led to about a 12% weight loss over 68 weeks. Moreover, a combination of cagrilintide and semaglutide resulted in approximately a 22% weight loss in people with obesity but without diabetes in late-stage trials.
Amylin analogs, a new generation of weight loss drugs, have shown encouraging results in early trials. Eli Lilly's eloralintide and Novo Nordisk's cagrilintide have both demonstrated significant weight loss and health improvements. With phase 3 trials underway for eloralintide, the future of weight management treatment looks promising.
